Endogenous subclinical hyperthyroidism: Metabolic and cardiac parameters

European Journal of Internal Medicine

Volumn 18, Issue 5, 2007, Pages 423-429

  Psaltopoulou, T ^a   Ilias, I ^b   Toumanidis, S ^a   Mantzou, E ^b   Marafellia, P ^a   Piperingos, G ^b   Koutras, D A ^a   Alevizaki, M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Evgenidion Hospital   (Greece)

Author keywords

Cardiac parameters; Endogenous clinical hyperthyroidism; Endogenous subclinical hyperthyroidism; Metabolic parameters; Subclinical hyperthyroidism

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; SEX HORMONE BINDING GLOBULIN; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR PARAMETERS; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; ENDOGENOUS SUBCLINICAL HYPERTHYROIDISM; FEMALE; HEART INDEX; HEART OUTPUT; HEART RATE; HEART VENTRICLE CONTRACTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; THYROID HORMONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL;

EID: 34547660180     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2006.12.010     Document Type: Article

References (39)

1. Dimitriadis G.D., and Raptis S.A. Thyroid hormone excess and glucose intolerance. Exp Clin Endocrinol Diabetes 109 (2001) S225-S239
2. Dimitriadis G., Maratou E., Alevizaki M., et al. Thyroid hormone excess increases basal and insulin-stimulated recruitment of GLUT3 glucose transporters on cell surface. Horm Metab Res 37 (2005) 15-20
3. Faber J., Perrild H., and Johansen J. Bone gla protein and sex-hormone-binding globulin in nontoxic goiter: parameters of metabolic status at the tissue level. J Clin Endocrinol Metab 70 (1990) 49-55
4. Kumeda Y., Inaba M., Tahara H., et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85 (2000) 4157-4161
5. Klein I., and Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 344 (2001) 501-509
6. Biondi B., Palmieri E.A., Klain M., Schlumberger M., Filetti S., and Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 152 (2005) 1-9
7. Biersack H.J., Hartmann F., Rodel R., and Reinhardt M. Long term changes in serum T4, T3, and TSH in benign thyroid disease: proof of a narrow individual variation. Nuklearmedizin 43 (2004) 158-160
8. Hansen P.S., Brix T.H., Sorensen T.I., Kyvik K.O., and Hegedus L. Major genetic influence on the regulation of the pituitary-thyroid axis: a study of healthy Danish twins. J Clin Endocrinol Metab 89 (2004) 1181-1187
9. Burmeister L.A., and Flores A. Subclinical thyrotoxicosis and the heart. Thyroid 12 (2002) 495-499
10. Biondi B., Fazio S., Carella C., et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77 (1993) 334-338
11. Gurlek A., and Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 9 (1999) 539-543
12. Bauer D.C., Nevitt M.C., Ettinger B., and Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 82 (1997) 2931-2936
13. Biondi B., Fazio S., Carella C., et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 78 (1994) 1028-1033
14. Fazio S., Biondi B., Carella C., et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab 80 (1995) 2222-2226
15. Shapiro L.E., Sievert R., Ong L., et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of l-thyroxine. J Clin Endocrinol Metab 82 (1997) 2592-2595
16. Petretta M., Bonaduce D., Spinelli L., et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol 145 (2001) 691-696
17. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantifications in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
18. Lwanga S.K., and Lemeshow S. Sample size determination in health studies (1991), World Health Organization, Geneva
19. Franklyn J., Betteridge J., Holder R., Daykin J., Lilley J., and Sheppard M. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol (Oxf) 41 (1994) 425-432
20. Mudde A.H., Houben A.J., and Nieuwenhuijzen Kruseman A.C. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 41 (1994) 421-424
21. Faber J., Jensen I.W., Petersen L., Nygaard B., Hegedus L., and Siersbaek-Nielsen K. Normalization of serum thyrotropin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 48 (1998) 285-290
22. Nystrom E., Lundberg P.A., Petersen K., Bengtsson C., and Lindstedt G. Evidence for a slow tissue adaptation to circulating thyroxine in patients with chronic l-thyroxine treatment. Clin Endocrinol (Oxf) 31 (1989) 143-150
23. Surks M.I., Ortiz E., Daniels G.H., et al. Subclinical thyroid disease - scientific review and guidelines for diagnosis and management. JAMA 291 (2004) 228-238
24. Lukert B.P., Higgins J.C., and Stoskopf M.M. Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J Clin Endocrinol Metab 62 (1986) 1056-1058
25. Bambini G., Aghini-Lombardi F., Rosner W., et al. Serum sex hormone-binding globulin in amiodarone-treated patients. A marker for tissue thyrotoxicosis. Arch Intern Med 147 (1987) 1781-1785
26. Frevert E.U., Biester A., Muller M.J., Schmidt-Gayk H., von zur Muhlen A., and Brabant G. Markers of bone metabolism during short-term administration of thyroxine in healthy volunteers. Eur J Endocrinol 131 (1994) 145-149
27. Alevizaki M., Mantzou E., Cimponeriu A., Alevizaki C., and Koutras D. TSH may not be a good marker for adequate thyroid hormone replacement therapy. Wien Klin Wochenschr 117 (2005) 636-640
28. Campbell J., Day P., and Diamond T. Fine adjustments in thyroxine replacement and its effect on bone metabolism. Thyroid 6 (1996) 75-78
29. Loviselli A., Mastinu R., Rizzolo E., et al. Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy. Thyroid 7 (1997) 561-566
30. Ross D.S., Ardisson L.J., Nussbaum S.R., and Meskell M.J. Serum osteocalcin in patients taking l-thyroxine who have subclinical hyperthyroidism. J Clin Endocrinol Metab 72 (1991) 507-509
31. Faber J., and Gailloe A.M. Changes of bone mass during prolonged subclinical hyperthyroidism due to l-thyroxine treatment: a meta-analysis. Eur J Endocrinol 130 (1994) 350-356
32. Uzzan B., Campos J., Cucherat M., Novy P., Boissel J.P., and Perret G.Y. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 48 (1996) 285-290
33. Tauchmanova L., Nuzzo V., Del Puente A., et al. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas 48 (2004) 299-306
34. Loviselli A., Rizzolo E., Mastinu R., et al. High serum circulating telopeptide type I in multinodular goiter. Horm Metab Res 35 (2003) 377-381
35. Brenta G., Schnitman M., Gurfinkiel M., et al. Variations of sex hormone-binding globulin in thyroid dysfunction. Thyroid 9 (1999) 273-277
36. Sgarbi J.A., Villaca F., Garbeline B., Villar H.E., and Romaldini J. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism on clinical and heart abnormalities. J Clin Endocrinol Metab 88 (2003) 1672-1677
37. Boutin J.M., Matte R., D'Amour P., et al. Characteristics of patients with normal T3 and T4 and a low TSH response to TRH. Clin Endocrinol (Oxf) 25 (1986) 579-588
38. Faber J., Wiinberg N., Schifter S., and Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 145 (2001) 391-396
39. Biondi B., Palmieri E.A., Fazio S., et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 85 (2000) 4701-4705